The disclosure relates to the use of a VLA-4 binding protein in the manufacture of a medicament for the treatment of multiple sclerosis wherein the medicament is: formulated for administration to a subject who previously received treatment with a first agent and who has experienced at least one relapse formulated for administration when the first agent is not present at a therapeutic level in the subject and formulated for continued administration in the absence of the first agent for at least four months, wherein the first agent is selected from the group consisting of an interferon, glatiramer acetate, a fumarate, mitoxantrone, a chemotherapeutic, an immunoglobulin, a statin, azathioprine, and a TNF antagonist. The first agent may be interferon beta and the VLA-4 binding antibody may be natalizumab.
